Fig. 1

(A) Overall Survival analysis of all MCD patients. (B) Progression Free Survival analysis of all MCD patients. (C) Subgroup Overall Survival analysis of MCD patients based on best treatment response. (D) Subgroup Progression Free Survival analysis of MCD patients based on best treatment response. (E) The Swimmer’s plot shows the dynamic responses and different continuous therapies of MCD patients. The horizontal axis represents the duration of continuous therapy after patients achieved their best response. (F) Sankey plot illustrates the progression from the initial treatment regimen to the best response, and subsequently, to various continuous treatment options. (G) Subgroup Analysis of Overall Survival by Continuous Therapy. (H) Subgroup Analysis of Progression-Free Survival by Continuous Therapy

Abbreviations: MCD (multicentric Castleman disease); CR (Complete Response); PR (Partial Response); SD (stable disease); PD (progressive disease); BCD (bortezomib, cyclophosphamide, and dexamethasone); BD (bortezomib, and dexamethasone); CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone); HV (hyaline vascular); RCD (rituximab, cyclophosphamide, dexamethasone); RD (rituximab, dexamethasone); R-CHOP/R plus glucocorticoids (R, rituximab); RVD (rituximab, bortezomib, dexamethasone); CT (Continuous Therapy);